Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- ("Triple") wild type melanomas.

doi:10.1016/j.ejca.2024.114208

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- ("Triple") wild type melanomas.

European journal of cancer (Oxford, England : 1990) - 1 Sept 2024

Jansen Philipp, Galetzka Wolfgang, Lodde Georg C, Standl Fabian, Zaremba Anne, Herbst Rudolf, Terheyden Patrick, Utikal Jochen, Pföhler Claudia, Ulrich Jens, Kreuter Alexander, Mohr Peter, Gutzmer Ralf, Meier Friedegund, Dippel Edgar, Weichenthal Michael, Placke Jan-Malte, Landsberg Jennifer, Möller Inga, Sucker Antje, Paschen Annette, Hadaschik Eva, Zimmer Lisa, Livingstone Elisabeth, Schadendorf Dirk, Ugurel Selma, Stang Andreas, Griewank Klaus G

Abstract excerpt

BACKGROUND: Melanomas lacking mutations in BRAF, NRAS and NF1 are frequently referred to as "triple wild-type" (tWT) melanomas. They constitute 5-10 % of all melanomas and remain poorly characterized regarding clinical characteristics and response to therapy. This study investigates the largest multicenter collection of tWT-melanomas to date. METHODS: Targeted next-generation sequencing of the TERT promoter and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to GTP Phosphohydrolases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Melanoma

Share to Neurofibromin 1

Share to Programmed Cell Death 1 Receptor

Share to Progression-Free Survival

Share to Skin Neoplasms

Share to Telomerase

Source

Open in PubMed

Identifiers

PMID: 39018633
DOI: 10.1016/j.ejca.2024.114208

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- ("Triple") wild type melanomas.PMID 39018633Read ↗

NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors.Semantic proximity Read ↗

TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy.Semantic proximity Read ↗

Integrated molecular drivers coordinate biological and clinical states in melanoma.Semantic proximity Read ↗

TERT expression is associated with metastasis from thin primaries, exhausted CD4+ T cells in melanoma and with DNA repair across cancer entities.Semantic proximity Read ↗

<i>TERT</i> expression is associated with metastasis from thin primaries, exhausted CD4+ T cells in melanoma and with DNA repair across cancer entitiesSemantic proximity Read ↗

Varying Mutational Alterations in Multiple Primary Melanomas.Semantic proximity Read ↗

The immune response-related genomic alterations in patients with malignant melanoma.Semantic proximity Read ↗

Landscape of mutations in early stage primary cutaneous melanoma: An InterMEL study.Semantic proximity Read ↗

TERT promoter mutations and melanoma survival: A comprehensive literature review and meta-analysis.Semantic proximity Read ↗

Assessing melanoma prognosis: the interplay between patient profiles, survival, and BRAF, NRAS, KIT, and TWT mutations in a retrospective multi-study analysis.Semantic proximity Read ↗

Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.Semantic proximity Read ↗

NF1-mutated melanoma tumors harbor distinct clinical and biological characteristics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.